Paying users zone. Data is covered by hidden.

  • Get 1 month access to Gilead Sciences Inc. for $17.99, or

  • get full access to entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

Microsoft Excel LibreOffice Calc

Gilead Sciences Inc. (GILD)


Common Stock Valuation Ratios (Price Multiples)

Difficulty: Beginner


Current Valuation Ratios

Gilead Sciences Inc., current price multiples

Microsoft Excel LibreOffice Calc
Gilead Sciences Inc. Abbott Laboratories AbbVie Inc. Allergan PLC Amgen Inc. Biogen Inc. Bristol-Myers Squibb Co. Celgene Corp. Eli Lilly & Co. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Pharmaceuticals & Biotechnology Health Care
Selected Financial Data
Current share price (P) $hidden
No. shares of common stock outstanding hidden
Growth rate (g) hidden
 
Earnings per share (EPS) $hidden
Next year expected EPS $hidden
Operating profit per share $hidden
Sales per share $hidden
Book value per share (BVPS) $hidden
Ratios (Price Multiples)
Price to earnings (P/E) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price to next year expected earnings hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price-earnings-growth (PEG) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price to operating profit (P/OP) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price to sales (P/S) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden
Price to book value (P/BV) hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-26).

If company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.

Otherwise, if company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Gilead Sciences Inc., historical price multiples

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Price to earnings (P/E) hidden hidden hidden hidden hidden
Price to operating profit (P/OP) hidden hidden hidden hidden hidden
Price to sales (P/S) hidden hidden hidden hidden hidden
Price to book value (P/BV) hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

Ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Gilead Sciences Inc.’s P/E ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Gilead Sciences Inc.’s P/OP ratio increased from 2016 to 2017 and from 2017 to 2018.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Gilead Sciences Inc.’s P/S ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Gilead Sciences Inc.’s P/BV ratio increased from 2016 to 2017 but then declined significantly from 2017 to 2018.

Price to Earnings (P/E)

Gilead Sciences Inc., historical P/E calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (USD $)
Net income attributable to Gilead (in millions) hidden hidden hidden hidden hidden
Earnings per share (EPS)2 hidden hidden hidden hidden hidden
Share price1, 3 hidden hidden hidden hidden hidden
Ratio
P/E ratio4 hidden hidden hidden hidden hidden
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/E Ratio, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/E Ratio, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

1 Data adjusted for splits and stock dividends.

2 2018 Calculation
EPS = Net income attributable to Gilead ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

3 Close price on the filing date of Gilead Sciences Inc.’s Annual Report.

4 2018 Calculation
P/E ratio = Share price ÷ EPS
= hidden ÷ hidden = hidden

5 Click competitor name to see calculations.

Ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Gilead Sciences Inc.’s P/E ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018.

Price to Operating Profit (P/OP)

Gilead Sciences Inc., historical P/OP calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (USD $)
Income from operations (in millions) hidden hidden hidden hidden hidden
Operating profit per share2 hidden hidden hidden hidden hidden
Share price1, 3 hidden hidden hidden hidden hidden
Ratio
P/OP ratio4 hidden hidden hidden hidden hidden
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/OP Ratio, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/OP Ratio, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

1 Data adjusted for splits and stock dividends.

2 2018 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

3 Close price on the filing date of Gilead Sciences Inc.’s Annual Report.

4 2018 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= hidden ÷ hidden = hidden

5 Click competitor name to see calculations.

Ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Gilead Sciences Inc.’s P/OP ratio increased from 2016 to 2017 and from 2017 to 2018.

Price to Sales (P/S)

Gilead Sciences Inc., historical P/S calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (USD $)
Product sales (in millions) hidden hidden hidden hidden hidden
Sales per share2 hidden hidden hidden hidden hidden
Share price1, 3 hidden hidden hidden hidden hidden
Ratio
P/S ratio4 hidden hidden hidden hidden hidden
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/S Ratio, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/S Ratio, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

1 Data adjusted for splits and stock dividends.

2 2018 Calculation
Sales per share = Product sales ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

3 Close price on the filing date of Gilead Sciences Inc.’s Annual Report.

4 2018 Calculation
P/S ratio = Share price ÷ Sales per share
= hidden ÷ hidden = hidden

5 Click competitor name to see calculations.

Ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Gilead Sciences Inc.’s P/S ratio increased from 2016 to 2017 but then slightly declined from 2017 to 2018.

Price to Book Value (P/BV)

Gilead Sciences Inc., historical P/BV calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
No. shares of common stock outstanding1 hidden hidden hidden hidden hidden
Selected Financial Data (USD $)
Total Gilead stockholders’ equity (in millions) hidden hidden hidden hidden hidden
Book value per share (BVPS)2 hidden hidden hidden hidden hidden
Share price1, 3 hidden hidden hidden hidden hidden
Ratio
P/BV ratio4 hidden hidden hidden hidden hidden
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
P/BV Ratio, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
P/BV Ratio, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

1 Data adjusted for splits and stock dividends.

2 2018 Calculation
BVPS = Total Gilead stockholders’ equity ÷ No. shares of common stock outstanding
= hidden ÷ hidden = hidden

3 Close price on the filing date of Gilead Sciences Inc.’s Annual Report.

4 2018 Calculation
P/BV ratio = Share price ÷ BVPS
= hidden ÷ hidden = hidden

5 Click competitor name to see calculations.

Ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Gilead Sciences Inc.’s P/BV ratio increased from 2016 to 2017 but then declined significantly from 2017 to 2018.